NeoThermaLogo_2018_1.jpg
NeoTherma Oncology Announces FDA IDE Submission to Permit Investigational Treatment of Pancreatic Cancer Patients with Its FDA-Designated Breakthrough Device, the VectRx™ Thermal Oncology System
January 09, 2020 09:00 ET | NeoTherma Oncology
WICHITA, Kan., Jan. 09, 2020 (GLOBE NEWSWIRE) -- NeoTherma Oncology (NTO), a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces they...
NeoTherma Oncology Receives NCI Grant to Advance VectRx™ MRI Thermometry
August 21, 2018 12:00 ET | NeoTherma Oncology
WICHITA, Kan., Aug. 21, 2018 (GLOBE NEWSWIRE) -- NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the...
NeoTherma Oncology Raises $6 Million to Advance VectRx™ to Human Testing
August 14, 2018 15:04 ET | NeoTherma Oncology
WICHITA, Kan., Aug. 14, 2018 (GLOBE NEWSWIRE) -- NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the...
NeoTherma Oncology Reports on the Safety and Effectiveness of RF-generated Heat Delivery in Preclinical Animal Studies with the Vectron TTx Thermal Device intended for Treatment of Deep Solid Tumors at Society for Thermal Medicine Annual Meeting
May 10, 2017 16:33 ET | NeoTherma Oncology
WICHITA, Kan., May 10, 2017 (GLOBE NEWSWIRE) -- NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, reported the results of a...
NeoTherma Oncology Announces FDA Granted Its Vectron Thermal Device for Treatment of Pancreatic Cancer Breakthrough Device Designation within Expedited Access Pathway
April 04, 2017 10:06 ET | NeoTherma Oncology
WICHITA, Kan., April 04, 2017 (GLOBE NEWSWIRE) -- NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces that...